Paper Details

  1. Home
  2. Paper Details

Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.

Author: BrunoBenedetto, CimminielloMichele, ConsoleGiuseppe, FedeleRoberta, FestucciaMoreno, GavarottiPaolo, MartinoMassimo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Standard treatment for Hodgkin lymphoma (HL) that returns after treatment or doesn't respond to initial treatment (relapsed/refractory, R/R) includes chemotherapy followed by a stem cell transplant from the patient's own body (AUTO-SCT). However, about half of patients relapse after this, and their outlook is poor. Brentuximab Vedotin (BV) has shown promise in treating these patients, and a transplant from a donor (ALLO-SCT) may offer a cure for some.
Paper Details　
Original Abstract of the Article :
Second-line, salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (AUTO-SCT) is the standard of care for patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). Approximately 50% of patients relapse after AUTO-SCT and their prognosis is generally po...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14712598.2015.1130821

データ提供：米国国立医学図書館（NLM）

Navigating Relapsed/Refractory Hodgkin Lymphoma: A Search for Effective Treatment Options

Hodgkin lymphoma, like a persistent desert sandstorm, can be a formidable challenge. This study, like a skilled physician seeking to overcome a difficult medical situation, explores the treatment options for relapsed/refractory Hodgkin lymphoma, a particularly challenging subtype of this disease. The study provides an overview of current treatment approaches, including salvage chemotherapy, high-dose chemotherapy with autologous stem cell transplantation, and allogeneic stem cell transplantation. The researchers highlight the role of brentuximab vedotin and newer agents in treating relapsed/refractory Hodgkin lymphoma, offering hope for patients facing this challenging condition.

Advancing Treatment for Relapsed/Refractory Hodgkin Lymphoma

This study offers a valuable resource for healthcare professionals treating patients with relapsed/refractory Hodgkin lymphoma. The research provides an overview of current treatment approaches and highlights promising new agents that could improve outcomes for these patients.

The Ongoing Quest for Effective Treatments

This research underscores the ongoing quest for effective treatments for relapsed/refractory Hodgkin lymphoma. The development of new agents and treatment strategies is a testament to the dedication of researchers and clinicians in their pursuit of better patient outcomes.

Dr. Camel's Conclusion

This study, like a well-equipped caravan navigating a treacherous terrain, explores the treatment landscape for relapsed/refractory Hodgkin lymphoma. The research highlights the importance of ongoing research and development in the quest for more effective and personalized therapies for this challenging disease.

Date :
  1. Date Completed 2016-10-05
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

26652934

DOI: Digital Object Identifier

10.1517/14712598.2015.1130821

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.